Kronox Lab Sciences Limited, a prominent player in the chemical industry, has made several key announcements following its recent Board of Directors meeting. The company has set the stage for its upcoming Annual General Meeting (AGM) and made important decisions regarding leadership and auditor appointments.

AGM and Dividend Details

The company has scheduled its 16th Annual General Meeting for August 18, 2025. In preparation for this event, Kronox Lab Sciences has set book closure dates from August 9 to August 18, 2025 (both days inclusive). This period will be used for AGM purposes and to determine the entitlement for the final dividend for the financial year 2024-25, if declared at the AGM.

Leadership Reappointments

The Board has approved the reappointment of three key executives for three-year terms, effective September 1, 2025:

• Mr. Ketan Ramani has been reappointed as Managing Director. He brings over three decades of chemical industry experience in finance, purchase, and administration.
• Mr. Jogindersingh Jaswal has been reappointed as Whole Time Director, responsible for production, quality control, and HR activities.
• Mr. Pritesh Ramani has been reappointed as Whole Time Director, managing sales and marketing operations.

These reappointments are subject to shareholder approval at the upcoming AGM.

Auditor Appointments

The company has made several new auditor appointments:

1. Secretarial Auditors: M/s. Devesh Pathak & Associates have been appointed as Secretarial Auditors for a five-year term.
2. Internal Auditors: M/s. Jaimin & Associates have been appointed as Internal Auditors.
3. Cost Auditors: M/s. Diwanji & Associates have been appointed as Cost Auditors for the financial year 2025-26.

These appointments demonstrate Kronox Lab Sciences' commitment to maintaining strong corporate governance practices.

The upcoming AGM on August 18, 2025, will be a crucial event for shareholders to ratify these decisions and set the course for the company's future.

Kronox Lab Sciences , a prominent player in the pharmaceutical industry, has unveiled its financial results for the fourth quarter, showcasing a mixed performance with growth in revenue and net profit, albeit with a decline in EBITDA margin.

Revenue Growth

The company reported a significant increase in revenue for Q4, reaching ₹261.00 crore, up from ₹222.00 crore in the same quarter of the previous year. This represents a robust year-over-year growth of approximately 17.57%, indicating strong market demand for Kronox Lab Sciences' products and services.

Profitability Metrics

Net Profit

Kronox Lab Sciences demonstrated improved bottom-line performance in Q4:

The year-over-year increase in net profit stands at about 6.78%, reflecting the company's ability to translate higher revenues into improved profitability. However, there was a slight sequential decline of approximately 3.08% compared to the previous quarter.

EBITDA Performance

While the company saw growth in revenue and net profit, its EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) performance showed some pressure:

The EBITDA saw a marginal year-over-year decline of about 2.53%.

Margin Analysis

The EBITDA margin for Kronox Lab Sciences experienced a notable contraction:

This represents a significant decrease of 5.82 percentage points in the EBITDA margin. The decline in margin despite revenue growth suggests increased operational costs or pricing pressures in the market.

Conclusion

Kronox Lab Sciences' Q4 results present a nuanced picture of the company's performance. While the firm has successfully grown its revenue and maintained profitability growth, the compression in EBITDA margin indicates challenges in maintaining operational efficiency. The company's ability to manage costs and improve margins while sustaining top-line growth will be crucial for its financial health in the coming quarters.